Identification of Integrin ab Expression in Lung Cancer Patients

Identification of Integrin ab Expression in Lung Cancer Patients for Clinical Application of Cancer-Target Fluorescent Contrast Agent for Image-Induced Precise Lung Cancer Surgery

It has been reported that the expression rates of integrin αvβ3 and integrin αvβ5 in NSCLC are 89% and 100%, respectively. Among RGD (Arg-Gly-Asp) peptides, cRGDyK peptide (cRGD) known as integrin ανβ3 and ανβ5 antagonist has been widely used for targeting various cancers including NSCLC, glioblastoma, and colon carcinoma as well as prostate cancer. In this study, the investigators aim to analysis the expression of integrin ανβ3 in lung cancer patients.

Study Overview

• Status: Completed
• Conditions: Expression of Integrin ανβ3 in Lung Cancer
• Intervention / Treatment: Biological: Lung cancer types

Detailed Description

Patient samples: From the Human Resource Bank of the Institute of Pathology, Korea University, the investigators collected paraffin-embedded tissue sections from 61 patients with NSCLC (adenocarcinoma =50, squamous cell carcinoma = 11) who had undergone surgical treatment for NSCLC at Korea University Guro Hospital between 2015 and 2018 under the IRB of Guro Hospital 2019GR0460. Samples were excluded when patients had undergone perioperative chemo- or radiotherapy. Among the tissues excised from lung cancer patients, lung cancer and normal tissue were classified as pathologically, defined as normal tissue and cancer tissue, and stained with an integrin ανβ3 primary antibody.

• Study Type: Observational
• Enrollment (Actual): 61

Contacts and Locations

Study Locations

• Korea, Republic of
  • Seoul, Korea, Republic of, 08308
    • Department of Thoracic and Cardiovascular Surgery, Korea University Guro Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Probability Sample

Study Population

NSCLC (adenocarcinoma or squamous cell carcinoma) who had undergone surgical treatment for NSCLC at Korea University Guro Hospital between 2015 and 2018

Description

Inclusion Criteria:

• NSCLC (adenocarcinoma or squamous cell carcinoma) who had undergone surgical treatment for NSCLC at Korea University Guro Hospital between 2015 and 2018

Exclusion Criteria:

• patients had undergone perioperative chemo- or radiotherapy

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
lung cancer; adenocarcinoma and squamous carcinoma	Biological: Lung cancer types; Cancer tissue matched to normal tissue, all from the same patient

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
integrin expression level	Integrins expression level categorized to high and low	20 months

Collaborators and Investigators

• Sponsor: Korea University Guro Hospital
• Investigators: Study Director: Hyun Koo Kim, Korea University Guro Hospital

Study record dates

Study Major Dates

• Study Start (Actual): December 19, 2019
• Primary Completion (Actual): September 10, 2021
• Study Completion (Actual): November 25, 2021

Study Registration Dates

• First Submitted: November 20, 2023
• First Submitted That Met QC Criteria: December 10, 2023
• First Posted (Actual): December 13, 2023

Study Record Updates

• Last Update Posted (Actual): December 13, 2023
• Last Update Submitted That Met QC Criteria: December 10, 2023
• Last Verified: December 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Respiratory Tract Diseases; Neoplasms; Lung Diseases; Neoplasms by Site; Respiratory Tract Neoplasms; Thoracic Neoplasms; Lung Neoplasms
• Other Study ID Numbers: 2019GR0460

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No